Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 49

recruiting
3 987
countries
28
conditions
2 109

690 trials match your criteria

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Study of Zolbetuximab with Nab-Paclitaxel and Gemcitabine for Adults with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine

Study on Asciminib and Asciminib Hydrochloride for Patients with Chronic Myelogenous Leukemia in Chronic Phase After Two or More Tyrosine Kinase Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart

Neoplasm

Not recruiting

Study of ASP1570 Alone or with Pembrolizumab for Adults with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ASP1570

Osteoarthritis

Not recruiting

Study on the Effects of DFV890 for Pain Relief in Patients with Knee Osteoarthritis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:DFV890

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab

Neoplasm malignant

Not recruiting

Study on the Safety and Anti-tumor Effects of GEN1042 Alone or with Pembrolizumab and Chemotherapy in Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study on Nivolumab and Ipilimumab for Patients with Advanced Urothelial Cancer After Initial Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab

Study of MK-2870 and Chemotherapy for Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study on Livmoniplimab and Budigalimab with Chemotherapy for Adults with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab

Study of Ipatasertib with Trastuzumab and Pertuzumab for Patients with Advanced HER2-Positive Breast Cancer and PIK3CA Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipatasertib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.